Centrica’s CEO Earns £4.7M as Earnings Plunge 48%—Shareholders Revolt as Insiders Buy Just 111 Shares

The numbers tell a stark story of misalignment. While Centrica's underlying earnings slumped 48% to £814 million last year, its CEO, Chris O'Shea, received a total pay package of £4.73 million. That includes a £1.4 million annual bonus and £2.2 million in long-term share awards. The company's household supply business, a key profit driver, saw its earnings tumble 39% due to warmer weather and customer switching to cheaper tariffs. In this context, the CEO's pay packet looks disconnected from the operational reality.

This disconnect sparked a major revolt at the annual general meeting. Nearly 40% of shareholders voted against the board's pay plans, a clear signal of investor frustration. The vote wasn't a minor dissent; it was a significant rejection, with 39.98% of votes opposing the remuneration report. Leading proxy adviser Institutional Shareholder Services (ISS) had already recommended against the package, calling the pay rise "materially above those given to the wider workforce" and stating it was "not considered to be supported by cogent rationale."

The bottom line is a severe misalignment of interest. When the CEO's compensation is tied to company performance, a 48% earnings drop should trigger a meaningful pay cut, not a package that remains in the millions. The shareholder revolt shows that even institutional investors are questioning the board's judgment. It's a classic case where the smart money is betting against the pay plan, highlighting a lack of skin in the game at the top when the business is struggling.

Insider Trading: Skin in the Game or Pump and Dump?

The board's pay plan may be under fire, but what are the insiders actually doing with their own money? Recent filings show CEO Chris O'Shea and other executives bought shares under the company's Share Incentive Plan in February 2026. O'Shea picked up 111 shares, while Russell O'Brien bought 112 shares. The transactions were made at prices around £2.58 to £2.67, which is near the stock's current trading range.

This is a classic case of minimal conviction. Buying a few hundred shares at the current price level doesn't signal a major bet on a turnaround. It looks more like fulfilling a pre-arranged plan than a bold statement of confidence. When the CEO's pay is tied to performance, and the business is struggling, the smart money expects bigger, more meaningful purchases to demonstrate real skin in the game. These small, routine buys don't cut it.

The company itself has been a major buyer, however. Centrica completed a £2 billion share buyback in 2025. That move can support the stock price and is a direct way to return capital to shareholders. But it also benefits insiders who hold options or performance awards tied to share price. It's a double-edged sword: a positive signal for the stock, but one that can also enrich those at the top regardless of underlying operational health.

The bottom line is a lack of alignment. While the board pushes a generous pay package, the insider buying suggests a cautious, low-risk stance. For all the talk of transformation and future profitability, the current moves don't show the kind of aggressive conviction that would make a smart money bet. It's a setup where the company props up the stock, and the executives collect their pay, while the real work of fixing the underlying earnings slump remains undone.

The Financial Reality: Resilience or Risk?

The numbers paint a picture of a company under pressure. Centrica's core household energy supply business, the engine of its profits, saw earnings tumble 39% to £163 million last year. That drop was driven by a double whammy: warmer weather that reduced demand and a wave of customers switching to cheaper fixed tariffs. This operational headwind is the real story behind the CEO's pay package and the shareholder revolt.

Yet, the balance sheet shows some resilience. The company ended the year with a net cash position of £1.49 billion, a strong buffer. But this strength is being tested. UBS highlighted continued pressure in domestic receivables, where aged debt in retail has climbed sharply from £1.95 billion to £2.48 billion. Provisions for bad debt have also swelled. This is a critical vulnerability; the company is collecting less cash from customers even as it pays out billions in dividends and buybacks.

The forward view is a key test. Management has set a target to reach £1.7 billion EBITDA by end-2028. That's a significant increase from the current run-rate, which is already down from prior years. The path to that goal is unclear. UBS noted the company's guidance for 2026 was weak relative to forecasts, with the retail and optimisation segment's EBITDA range centering below expectations. The bank also flagged that annual rises in working capital were unsustainable for the industry, a direct hit to cash flow.

The bottom line is a tension between a solid cash pile and mounting operational risks. The smart money is watching where the cash goes next. With the share buyback paused to fund investments, the focus shifts to whether Centrica can fix its core supply business and manage its receivables before the cash buffer starts to erode. The target is ambitious, but the current trajectory shows more risk than resilience.

Catalysts and Risks: What to Watch

The shareholder revolt has forced a pause, but the real test is what happens next. The board has committed to provide an update to shareholders within six months of the AGM. That six-month window is now a key watchpoint. Any delay or vagueness in that promised engagement will signal a lack of urgency in addressing the fundamental misalignment that sparked the revolt.

For now, the smart money should watch for a stronger signal of confidence-or lack thereof-from the executives themselves. The recent insider buys, while routine, are small. The real catalyst will be any further share sales, especially if they coincide with a cut to earnings guidance. That would be a clear, cash-based vote of no confidence from those who know the business best. The current pattern of minimal buys under a Share Incentive Plan doesn't demonstrate the skin in the game that investors demand.

More broadly, the transformation programme is the only path to the ambitious £1.7 billion EBITDA target by end-2028. The company is making bold investments in projects like Sizewell C and Grain LNG. The smart money will monitor the progress of these capital-intensive initiatives. Are they on track and within budget? Any delays or cost overruns would directly threaten that future profitability target and could trigger another wave of skepticism.

The bottom line is that the near-term catalysts are about execution and transparency. The board has six months to show it's listening. The insiders have yet to make a meaningful bet. And the transformation programme must deliver to justify the future. Until then, the stock remains caught between a weak operational reality and a distant, unproven promise.